- Tuberculosis
- Latent Tuberculosis Treatment
- Active Tuberculosis Treatment
- Possibly Resistant Tuberculosis Treatment
- Multiple Drug Resistant Tuberculosis Treatment
- Tuberculosis Screening in Children
- Tuberculosis Risk Factors (Tuberculosis Screening Indications)
- Tuberculosis Risk Factors for progression from Latent to Active Disease (Latent Tuberculosis Treatment Indications)
- Tuberculosis Related Chest XRay Changes
- Extrapulmonary Tuberculosis
- Tuberculin Skin Test (TST, Purified Protein Derivative, PPD)
- Mycobacterium Tuberculosis Antigen-Specific Interferon-Gamma Release Assay (IGRA)
- Tuberculosis Resources
- Resistance rate in patient's Community <4%
- Most communities have Tb resistance >4%
- HIV Screening negative
- Immunocompetent
- No prior Tuberculosis Treatment
- Four Drug Therapy with Moxifloxacin and Rifapentine 4 Month Course (2022 Regimen)
- Background
- All but 1 of the medications are taken everyday with food for entire 119 day course
- Pyrazinamide is taken only for first 56 days only
- Shortens the course (better compliance)
- Reduces adverse effects compared to older regimens (reduced hepatotoxicity and ocular toxicity risk)
- Indications
- Age =12 years AND body weight =40 kg
- Pulmonary TB caused by organisms that are not known or suspected to be drug-resistant
- Contraindications
- Age <12 years or weight <40 kg
- Use the Ethambutol/Rifampin protocol for total of 4 months instead (see below)
- Pregnancy or Breastfeeding
- Requires 24 week course with a different regimen
- Extrapulmonary Tuberculosis (esp. CNS involvement)
- Age <12 years or weight <40 kg
- Phase 1: Intensive for first 8 weeks
- Rifapentine (RPT) 1200 mg orally daily
- Multiple Drug Interactions (HIV Medications, Opioids, contraceptives)
- Moxifloxacin (MOX) 400 mg orally daily
- Drug Interactions with iron, Magnesium and other cations
- Risk of QTc Prolongation
- Isoniazid (INH) 300 mg orally daily
- Take with Pyridoxine 25 to 50 mg orally daily (Peripheral Neuropathy prevention)
- Pyrazinamide (PZA, used for only first 8 weeks)
- Weight 40 to 55 kg: 1000 mg orally daily
- Weight 55 to 75 kg: 1500 mg orally daily
- Weight >75 kg: 2000 mg orally daily
- Rifapentine (RPT) 1200 mg orally daily
- Phase 2: Continuation for additional 9 weeks
- Rifapentine (RPT) 1200 mg orally daily
- Moxifloxacin (MOX) 400 mg orally daily
- Isoniazid (INH) 300 mg orally daily
- References
- Four Drug Therapy with Ethambutol and Rifampin 4-6 Month Course (Older Regimen)
- Background
- Adults and teens are recommended to have the above 4 month course (with Moxifloxacin and Rifapentine)
- Additional regimens are available with less frequent dosing, but with higher risk of failure
- See CDC website for other regimens
- Initial/Intensive phase: 3-4 drug regimen for 2 months
- Medications (4 used together in initial phase)
- Isoniazid (INH)
- Adult: 300 mg orally daily
- Child: 10 to 15 mg/kg (up to 300 mg) orally daily
- Take with Pyridoxine 25 to 50 mg orally daily (Peripheral Neuropathy prevention)
- Rifampin (RIF)
- Adult: 10 mg/kg/day (up to 600 mg) oral or IV daily
- Child: 10 to 20 mg/kg/day (up to 600 mg) oral or IV daily
- Multiple Drug Interactions (HIV Medications, Opioids, contraceptives)
- Pyrazinamide (PZA)
- Weight <40 kg: 35 mg/kg (up to 1000 mg) orally daily
- Weight 40 to 55 kg: 1000 mg orally daily
- Weight 55 to 75 kg: 1500 mg orally daily
- Weight >75 kg: 2000 mg orally daily
- Ethambutol (EMB, unless not indicated by culture)
- Dose based on estimated Lean Body Mass and reduce dose in Renal Insufficiency
- Child: 15-25 mg/kg (max 1000 mg/day) orally daily
- Adult: 15-25 mg/kg (max 1600 mg/day) orally daily
- Weight 40 to 55 kg: 800 mg/day
- Weight 56 to 75 kg: 1200 mg/day
- Weight 79 to 90 kg: 1600 mg/day
- Isoniazid (INH)
- Dose timing
- Take all four medications once daily for 8 weeks (56 doses, preferred) OR
- Take five times weekly for 8 weeks (40 doses)
- Given under direct observation
- Medications (4 used together in initial phase)
- Continuation phase: Double therapy for 2-7 months
- Medications (2 used together in continuation phase)
- Dose timing (18 weeks unless otherwise noted below)
- Once daily for 9 weeks has replaced longer courses
- Once daily (125 doses, preferred) or
- Five times per week (90 doses, under direct observation, preferred) or
- Three times per week (54 doses under direct observation, alternative when direct observation schedule is difficult)
- Duration of treatment
- Double therapy for 18 weeks unless exceptions below
- Indications for 7 month continuation phase
- Cavitary pulmonary Tuberculosis
- Positive Sputum Culture after initial phase
- Adjunctive
- Vitamin B6 (Pyridoxine) 25-50 mg daily
- Indicated for Neuropathy risk due to INH (e.g. Diabetes Mellitus, Alcoholism)
- See Isoniazid for details
- Vitamin B6 (Pyridoxine) 25-50 mg daily
- Monitoring
-
Liver Function Tests
- Obtain baseline and every 3 months during therapy
-
Serum Creatinine
- Obtain baseline and periodically ()
- Adjust doses of Ethambutol and Pyrazinamide accordingly
- CDC Tb Guidelines Treatment
- CDC Division of Tuberculosis Elimination